Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/2607
Title: Development of the Screening Tool for Everyday Mobility and Symptoms (STEMS) for skeletal dysplasia
Authors: Ireland, P. J.
Coussens, M.
Tate, T.
Pocovi, T.
Savarirayan, R.
Tofts, L.
Munns, C.
Pacey, V.
Issue Date: 2021
Source: 16, (1), 2021
Journal: Orphanet Journal of Rare Diseases
Abstract: Background: Skeletal dysplasia are genetic disorders of cartilage and bone, characterized by impairments commonly resulting in short stature, altered movement biomechanics, pain, fatigue and reduced functional performance. While current tools quantify functional mobility performance, they have not been standardly used in this population group and do not capture patient-reported symptoms such as pain or fatigue. This study evaluated a new tool, the Screening Tool for Everyday Mobility and Symptoms (STEMS), designed to accurately and objectively assess functional mobility and associated symptomology for individuals with skeletal dysplasia. Methods: Individuals aged 5–75 years with a skeletal dysplasia completed the STEMS, the Functional Mobility Scale (FMS) and Six Minute Walk Test (6MWT). The correlation among the STEMS, use of mobility aides, FMS and 6MWT normalised for leg length was calculated. One-way analysis of variance compared the STEMS symptomatology to normalised 6MWT distance. Results: One hundred and fifty individuals with skeletal dysplasia (76 achondroplasia, 42 osteogenesis imperfecta, 32 other; 74 < 18 years, 76 ≥ 18 years) participated. Almost two thirds of the group reported pain and/or fatigue when mobilising at home, at work or school and within the community, but only twenty percent recorded use of a mobility device. The STEMS setting category demonstrated highly significant correlations with the corresponding FMS category (r = − 0.983 to − 0.0994, all p < 0.001), and a low significant correlation with the normalised 6MWT distance (r = − 0.323 to − 0.394, all p < 0.001). A decreased normalised 6MWT distance was recorded for individuals who reported symptoms of pain and/or fatigue when mobilising at home or at work/school (all p ≤ 0.004). Those who reported pain only when mobilising in the community had a normal 6MWT distance (p = 0.43–0.46). Conclusions: The Screening Tool for Everyday Mobility and Symptoms (STEMS) is a useful new tool to identify and record mobility aide use and associated self-reported symptoms across three environmental settings for adults and children with skeletal dysplasia. The STEMS may assist clinicians to monitor individuals for changes in functional mobility and symptoms over time, identify individuals who are functioning poorly compared to peers and need further assessment, and to measure effectiveness of treatment interventions in both clinical and research settings.L20102177672021-02-02
2021-06-03
DOI: 10.1186/s13023-021-01681-z
Resources: https://www.embase.com/search/results?subaction=viewrecord&id=L2010217767&from=exporthttp://dx.doi.org/10.1186/s13023-021-01681-z |
Keywords: bone dysplasia;child;cohort analysis;controlled study;cross-sectional study;fatigue;female;functional assessment;Functional Mobility Scale;human;leg length;major clinical study;male;adult;osteogenesis imperfecta;pain;physical mobility;screening test;Screening Tool for Everyday Mobility and Symptoms;six minute walk test;symptomatology;walking distance;adolescent;walking aidachondroplasia;musculoskeletal disease assessment;aged;article
Type: Article
Appears in Sites:Children's Health Queensland Publications

Show full item record

Page view(s)

30
checked on Mar 20, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.